It is estimated that close to 40% of the world's 1.2 billion women will be post-menopausal or menopausal by 2030. That's nearly 50 million women and, among those, ~60-70% are likely to suffer from menopausal symptoms. Although hormone therapy (HT) is suggested for curtailing both vasomotor symptoms and mood disturbances, HT treatment continues to be controversial. Aside from breast cancer and cardiovascular concerns, research shows that HT itself might also increase the risk of depression.
In a recent discussion among OB-GYNs and primary care clinicians, about half stated they treat menopausal vasomotor symptoms with antidepressants such as SSRIs, SNRIs, and bupropion. While there was agreement that the treatment may not address all of the symptoms, research has confirmed that antidepressants are effective in treating both depression and vasomotor symptoms shortly before, during, and after menopause.
Which antidepressant(s) do you find most effective for the treatment of menopause? Have you observed whether these are the same antidepressants that work in younger women for premenstrual dysphoric disorder?
-
Leonardo Que2yrI would consider using Paroxetine for treatment of VMS if there is contraindications to use of hormonal Rx, risk of thromboembolism and breast cancer with the use of Estrogen, change Show More -
William DeMedio2yrSSRI’s as a class all work excellently in their relief of VMS of menopause. The longest acting, best studied, and most economical in the class is fluoxetine. A simple daily Show More
